Danaher, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Daniel Brennan from TD Cowen maintained a Buy rating on the stock and has a $260.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Daniel Brennan has given his Buy rating due to a combination of factors that highlight Danaher’s potential for future growth. Despite a mixed performance in the third quarter and initial fourth-quarter guidance, Danaher has demonstrated strong earnings growth, particularly with a notable 10% EPS beat. This growth is attributed to proactive cost management and strategic reinvestment, which positions the company well for future challenges and opportunities.
Moreover, the company’s guidance for 2026 suggests a conservative starting point for organic growth, which could lead to high single-digit EPS growth. This conservative outlook provides a cushion for potential upside, especially if there is a recovery in bioprocessing equipment demand and improvements in the Life Sciences and China Diagnostics sectors. These factors collectively offer a compelling entry point for investors looking for a strong secular growth story, prompting Brennan to raise the price target and maintain a Buy rating.
In another report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $240.00 price target.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DHR in relation to earlier this year.